synthetic, single stranded, fully phosphorothioated 2’-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs) | |
---|---|
Trade Name | |
Orphan Indication | Dravet Syndrome |
USA Market Approval | USA |
USA Designation Date | 2017-03-16 00:00:00 |
Sponsor | OPKO Ireland Global Holdings Ltd.;10 Market Street, Suite 721;Camana Bay |